Ablynx wins award for 'Most successful early phase trial"
Commenting on the award, Chief Medical Officer Josi Holz said: “It is a great honour to receive this prestigious award. We are pleased that our lead programme, a novel anti-thrombotic, ALX-0081 entered a Phase II study in patients undergoing percutaneous coronary intervention (PCI) last month. The award recognises our innovative Phase I clinical trial design and the acceleration of this programme through the use of biomarkers and PK/PD modelling to establish biological effective dosing in patients. We have achieved the rapid progress with ALX-0081 thanks to a dedicated Ablynx team and our collaborators at the OLVZ in Aalst and PRA International.”
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.